The road to Tau

Asceneuron plans to show power of tau in AD by first tackling Orphan tauopathy

Asceneuron S.A. is working to treat neurodegeneration by preventing formation of neurofibrillary tangles in the hopes this mechanism will fare better in treating Alzheimer's disease than amyloid-targeted products.

Neurofibrillary tangles arise when microtubule-associated protein tau (tau; MAPT; FTDP-17) aggregates into helical filaments and larger structures, a process associated with tau hyperphosphorylation. Glycosylation by enzymes such as O-linked N-acetylglucosamine (GlcNAc) transferase (OGT) protects against tau hyperphosphorylation; however, this glycosylation is reversed by the enzyme

Read the full 743 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE